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 In the age of big data, thoughtful management and harmonization of clinical 
metadata and sample processing in translational research is a critical for effective data 
generation, integration, and analysis. These steps enable the cutting edge discoveries and 
enhance overall conclusions that may come from complex multi-omic translational 
research studies. The focus of my thesis has been on harmonizing the clinical metadata 
collected as part of the lung Pre Cancer Genome Atlas (PCGA) in addition to expanding 
the use of banked samples. The lung PCGA study included longitudinal collected 
samples and data from participants in a high-risk lung cancer-screening program at 
Roswell Park Comprehensive Cancer Center (Roswell) in Buffalo, NY. Clinical metadata 
for this study was collected over many years at Roswell and subsets of this data were 
shared with Boston University Medical Campus (BUMC) for the lung PCGA study. 
During the study, additional clinical metadata was acquired and shared with BUMC to 
complement the analysis of genomic profiling of DNA and RNA, as well as protein 
staining of tissue. With regards to the PCGA study, my thesis has two aims: 1) Curate the 
clinical metadata from received from Roswell during the PCGA study to enhance both its 
accessibility to current investigators and collaborators and reproducibility of results 2) 
	
	 vi 
Test methods to isolate DNA from remnant samples to expand the use of banked samples 
for genomic profiling. We hypothesized that the accomplishment of these goals would 
allow for increased use of the clinical metadata, enhanced reproducibility of the results, 
and expansion of samples available for DNA sequencing 
The clinical metadata received from Roswell was consolidated into a singular 
source that is continually updated and available for export for future research use. These 
metadata management efforts led to increased use among the members of our laboratory 
and collaborators working with the lung PCGA cohort. Additionally, the curation of 
metadata has allowed for improved analysis, reproducibility, and increased awareness of 
the current inventory of remaining samples. 
During the process of lung PCGA clinical metadata curation, physical inventory 
of the remaining samples revealed remnant organic phase samples. Therefore, in addition 
to my work associated with clinical metadata, the second goal of my thesis focuses on 
DNA isolation from remnant banked biological samples from the lung PCGA cohort. In 
the first phase of the lung PCGA, nucleic acid isolation of RNA was intended to be 
collected exclusively from fresh frozen endobronchial biopsy samples, and formalin-
fixed paraffin embedded (FFPE) biopsy samples were to be used for DNA isolation. 
DNA isolation from the FFPE samples was unsuccessful. However, from the RNA 
isolation, the remaining organic phase was banked and could potentially serve as a source 
of DNA. The organic phase of this isolation contained cell debris, proteins, and, as 
previously mentioned, DNA. We hypothesized that current protocols for organic phase 
DNA isolation might yield adequate quantities of DNA for genomic profiling. Utilizing 
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immortalized cell culture lines to establish methodology, numerous organic phase DNA 
isolation protocols were tested. During subsequent validation using the remaining organic 
phase samples from the lung PCGA cohort, the protocol yielded varied results, 
suggesting that further optimization to increase DNA purity is required. The ability to 
isolate DNA from these valuable samples will enhance progress in the lung PCGA study. 
The aims of this thesis involving curation of clinical metadata and generation of 
additional DNA samples for DNA profiling has had significant impact on the PCGA 
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The Current Clinical Landscape of Lung Cancer  
Currently, lung cancer is the leading causes of all cancer deaths worldwide with a 
20% 5-year survival rate. (Paul, 2020) Lung cancer is also the deadliest cancer in the 
United States, with an estimated mortality that is greater than the combined deaths due to 
breast, prostate, and colon or rectal cancer deaths.  Approximately 2.09 million new cases 
were diagnosed worldwide in 2018 with an estimated 1.76 million deaths, making lung 
cancer the most frequent cancer diagnosed and cancer related cause of death for men and 
women globally. (Bade & Dela Cruz, 2020) A large majority of the diagnosed cases 
occur in the advanced stages of the disease. Patients who are diagnosed at an early stage 
such as Stage 1A have a 92% chance of survival outside the 5-year window, versus 
patients who are diagnosed at Stage 4, which have less than 10% survivability. 
(Pietrangelo, 2019) The detection of lung cancer at early and even pre-malignant stage 
may be a path to increasing survivorship of patients, which is challenging in a clinical 
setting due to the initial asymptomatic presentation prior to metastases.   
There are two major types of lung cancer, Non-Small Cell Lung Cancer (NSCLC) 
and Small Cell Lung Cancer (SCLC), with SCLC accounting for only 15% of diagnosed 
cases, where most cases most cases identified are aggressive disease where limited 
therapeutic options are sustainable. NSCLC is further divided into 3 histologic subtypes: 
lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and large cell 
carcinoma. (Dela Cruz et al., 2011) Of these three different subtypes, there exist different 
risk factors associated with development of each. The major risk that is associated with 
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development of lung cancer is cigarette/tobacco smoking and exposure, but exposure to 
radon, asbestos, family history of lung cancer, age, and genetic factors have also been 
linked to increased risk. (Malhotra et al., 2016) Among the three subtypes, LUAD cases 
are diagnosed in non-smokers, former or active smoking populations, whereas LUSC is 
predominantly diagnosed in former or active smoking populations. Additionally, LUAD 
is commonly diagnosed in regions of the lung that are more peripheral as compared to 
LUSC, which is diagnosed in the proximal bronchial airways. The implementation of 
screening has enhanced the detection of LUAD, however, patients at risk with no 
associated smoking history are challenging to identify, as they do not qualify for lung 
cancer screening under the current guidelines. The current National Comprehensive 
Cancer Network (NCCN) guidelines for screening include patients who are above the age 
of 50 and have a smoking history (20+ pack years), in addition to other risk factors 
including occupational exposure to carcinogens or have a family history of lung cancer. 
(Wood et al., 2018)(Myers & Wallen, 2020)  
 
Screening and Diagnostic Tools for the Detection of Lung Cancer 
Within the past decade there has been an increased emphasis on the use of 
screening techniques in patients who have risk factors for all forms of cancer. Overall, 
these particular screening techniques have led to an increase in 5-year survival for 
thousands of patients in the United States alone. (Merrick, 2019) Though techniques are 
being used to detect the presence of lung cancer prior to metastases, there still exists 
continued focus on improvement of early detection. The National Lung Screening Trial 
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(NLST) approached this challenge and randomized a cohort of over 50,000 patients into a 
two arm study to evaluate lung cancer mortality when screening with low-dose Computed 
Tomography (CT) scans compared to chest radiography. These analyses revealed that 
annual screening by low-dose CT scans reduced lung cancer mortality in the screened 
population. (“Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic 
Screening,” 2011) Annual or semi-annual CT scans are currently the most common 
approved diagnostic technique for lung cancer screening using the NCCN guidelines 
stated above, although research studies also use Positron Emission Tomography (PET) 
scanning, in addition to auto-fluorescent and narrow band bronchoscopy procedures. 
Bronchoscopy procedures used for additive screening in research settings, have 
sensitivity ranging from 50-60% for the detection of lung cancer. (Billatos et al., 2018)  
These diagnostic techniques hold validity with proven specificity and sensitivity 
of diagnoses for many locations within the lung; however, there are still many cases 
where patients’ asymptomatic presentations may not be screened and those screened may 
have unclear, non-diagnostic results that delay detection. (Radha et al., 2014) Patients 
with non-diagnostic bronchoscopy examinations undergo follow-up invasive procedures 
associated with increased complication rates. These non-diagnostic bronchoscopy 
examinations are common, revealing the sub-optimal capabilities associated with this 
procedure, and emphasizing a need for improved diagnostic tools. For these reasons, our 
group has built, validated, and commercialized a gene expression-based diagnostic 
biomarker to detect the presence of cancer through airway brushings obtained during 
bronchoscopy to prevent unnecessary invasive follow-up procedures. (Silvestri et al., 
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2015)(Whitney et al., 2015) Our group is also actively building biomarkers to predict a 
patient’s risk of developing lung cancer. (J. Beane et al., 2017) 
A biomarker is a naturally occurring molecule, set of genes, or biological entity 
that is altered during the pathologic process of a disease, and thus can be used to detect 
the early stages of disease. In the current field of medical diagnostics, biomarkers are 
used for disease diagnostics/prognostics, monitoring, and predictive purposes. One of 
these classes, a diagnostic biomarker, is used to detect or confirm the presence of a 
disease or condition of interest, or identifies an individual with a subtype of the disease. 
(Califf, 2018) (Prabhakar et al., 2018)  
The Percepta Bronchial Genome Classifier is an example of a biomarker that is 
currently used within the clinical landscape of lung cancer diagnostics. The 23-gene 
genomic classifier was identified using gene expression profiling of bronchial brushes 
from the mainstem bronchus in current and former smokers undergoing bronchoscopy for 
suspicion of lung cancer. (Spira et al., 2007) (Whitney et al., 2015)(Silvestri et al., 2015) 
The Percepta biomarker had 88% sensitivity and a 91% negative predictive value in 
patients with a physician-determined indeterminate pretest probability. (Billatos et al., 
2018) Percepta’s use in the clinical space has aided physicians in the decision-making 
process for intermediate risk patients, and is an example of how molecular biomarkers 
can impact clinical decision-making and patient care. In conjunction with Percepta’s 
validation, Perez-Rogers and collaborators performed analysis of cytology nasal brushes 
to evaluate the capability to use nasal epithelium gene expression alterations as a lung 
cancer detection biomarker. Due to the concordant response of nasal and bronchial 
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epithelium to tobacco smoke, they hypothesized and concluded that nasal epithelium 
gene expression alterations have the potential to be used as a lung cancer detection 
biomarker. (Perez-Rogers et al., 2017)  
 
Bronchial Pre-Malignant Lesions and the Development of LUSC 
LUSC is significantly associated with tobacco/cigarette smoking. Tobacco smoke 
contains numerous carcinogens that cause damage and molecular changes to the 
epithelial cells that line the bronchial airway.  The pseudostratified lung epithelium is 
predominantly composed of ciliated, goblet, club, and basal cells. These epithelial cells 
act as a barrier against different toxic substances that are introduced from the external 
environment. Transcriptomic analysis by single cell RNA-sequencing of cells within the 
human bronchial epithelium from never smokers compared to current smokers revealed 
alterations in multiple cell populations and metabolic processes. Evaluation of cell 
populations revealed metabolic changes in ciliated cells pertaining to alterations in gene 
expression for enzymes capable of breaking down tobacco-smoke derived compounds. 
Goblet cell hyperplasia tissue remodeling with a loss of club cells was observed in the 
smoking population compared to healthy controls, and a subpopulation of goblet cells 
termed peri-goblet cells was also identified in the smoking population. Throughout these 
complex changes within the human bronchial epithelium, the cellular alteration reduces 
the capability for the pseudostratified epithelium of the lung to function as an effective 
barrier and increases the likelihood for disease development. (Duclos et al., 2019)  
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These cellular and molecular alterations can lead to histological changes known 
as premalignant lesions (PML), which are precursor lesions that occur in the stepwise 
process of the development of LUSC at that site or elsewhere within the lung. In 
particular the genes for the Electron Transport Chain (ETC) pathway, Oxidative 
Phosphorylation (OXPHOS) pathway, and mitochondrial protein transport pathways 
were all shown to be upregulated within the airway field of injury in the presence of 
PMLs compared to airways without PMLs. (J. Beane et al., 2017) (Billatos et al., 2018) 
The ability to identify molecular and histologic changes occurring in a particular PML in 
the non-involved upper airway could aid in developing biomarkers to predict which 
PMLs will develop into LUSC. 
 
Lung Pre-Cancer Genome Atlas (PCGA) Results  
The Lung Pre-Cancer Genome Atlas (PCGA) is a research study led by our 
research group in collaboration with Janssen Pharmaceuticals and Roswell Park 
Comprehensive Cancer Center aimed at identifying molecular changes associated with 
PML development and progression in a longitudinal study. The molecular 
characterization of bronchial PMLs has identified molecular subtypes of disease as well 
as somatic mutations associated with disease severity. Among these mutations and 
alterations, there exist previously defined genetic alterations that confer phenotypic 
changes that allow for proliferation of particular cells to become cancerous. (Duclos et 
al., 2019) (J. E. Beane et al., 2019) Comparing the genomic alterations from PCGA to the 
previously defined alterations, termed cancer proliferative driver mutations, could 
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elucidate the early events of cancer progression. The lung PCGA cohort and others have 
identified gene expression alterations affecting cell cycle and other metabolic pathways, 
as well as immune suppression, in high-grade bronchial PMLs. (J. E. Beane et al., 2019) 
(Mascaux et al., 2019) (Merrick et al., 2018) Our collaborators have also identified LUSC 
driver mutations associated with lung cancer progression in high-grade bronchial PMLs. 
(Teixeira et al., 2019) 
Our group also performed RNA-sequencing on the serially collected PML 
endobronchial biopsies and bronchial brushes. This data in conjunction with other LUSC-
related data sets identified nine gene co-expression modules that were used to determine 
the molecular subtypes of PMLs. Four molecular subtypes were identified within the 
discovery cohort of PCGA, termed Proliferative, Inflammatory, Secretory, and Normal-
like. These molecular subtypes of PMLs were further characterized by focusing on 
enriched or decreased expression of particular molecular pathways within each of the 
modules. (J. E. Beane et al., 2019) These four PML subtypes also correlated to previously 
identified LUSC subtypes from The Cancer Genome Atlas (TCGA) when compared on 
the basis of enriched molecular pathways. (Hammerman et al., 2012) Furthering this, the 
four molecular subtypes were replicated later in a validation set from the same cohort. 
Immune cell populations were also analyzed within the PML endobronchial biopsies. 
Cell populations were shown to have increases in the presence of type M1 macrophages, 
but decreases in M2 macrophages and CD8 T cells. (J. E. Beane et al., 2019) Further 
DNA-sequencing analysis of DNA samples isolated from endobronchial biopsies and 
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bronchial brushes is ongoing, but preliminary results have identified somatic alterations 
associated with lesion severity.  
 
Lung PCGA Study Design 
All biological samples in the lung PCGA cohort were collected at Roswell Park 
Comprehensive Cancer Center from high-risk lung cancer patients undergoing lung 
cancer screening via CT scan and autofluorescence bronchoscopy. Smoking history, age, 
race, lung cancer history, familial history of lung cancer, and presence of other 
pulmonary disease were all evaluated at the baseline collection date. The majority of 
study participants were above the age of 50, had previous or current smoking history, 
some had previously been diagnosed with lung cancer, and some had familial history of 
lung cancer. The patients received lung screening and bronchoscopy procedures at 
approximately 1-year intervals. Endobronchial biopsies and bronchial brushes were 
collected at each time point and then longitudinally during screening procedures for 
research purposes. The endobronchial biopsies were collected from numerous anatomic 
locations exhibiting abnormal fluorescence and the brushes were collected from a normal 
fluorescing region of the mainstem bronchus. In addition, one blood sample was collected 
from each patient. (J. E. Beane et al., 2019)  
Upon baseline sample collection each sample was assigned a numerical identifier 
that would be used to track the samples prior to shipment.  The endobronchial biopsies 
were collected and processed either by being fixed in formalin as a FFPE sample or 
stored as a fresh frozen tissue biopsy in RNA protect media. All bronchial brush samples 
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were also stored and frozen in RNA protect media. BUMC was selected as the core 
biorepository and processing site for the samples collected from the PCGA study, so all 
collected biological samples were shipped to BUMC to be stored and processed. Upon 
isolation of the endobronchial biopsies and brushes into RNA and DNA, each of the 
nucleic acid samples was given a different laboratory identifier by the members of the 
Spira laboratory at BUMC. During later sequencing processes each of these samples was 
tracked using their respective Spira laboratory identifier. Following all sequencing, the 
associated data for each sample was shared with computational analysts who then 
assigned another identifier termed the PCGA long ID. The PCGA long ID consisted of 
patient number, sample location collection code, days since birth of the patient on the day 
of bronchoscopy, original sample number, sample type, and corresponding program 
tracking number followed by an alphabetical identifier for DNA or RNA. With these 
many generated IDs, there became issues in connecting all sample identifiers to attempt 
to identify particular samples within our group and among collaborators. 
The protocol originally exclusively isolated RNA from the fresh frozen biopsies 
leaving the DNA in an un-isolated form as the organic phase, which was banked within 
the freezers at BUMC. Additionally, the original protocol intended to isolate DNA from 
collected FFPE endobronchial biopsies, however, these isolations were not successful. 
Many of the samples processed under the original protocol do not have corresponding 
DNA samples due to this reason. In later protocols within the lung PCGA cohort, both 
DNA and RNA were isolated from the fresh frozen lung biopsies.  
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Once samples were isolated and analyzed for nucleic acid concentration, optical 
density values, and any associated contamination, the sample information was delivered 
to the study coordinating team. Paired files, termed data dictionaries, containing 
descriptions of labeling, scoring, and coding were created for all generated files. These 
data dictionaries became valuable resources for understanding the information and 
formatting contained in study files. All of the information and sample identifiers were 
then logged into computer files and clinical data management software. Throughout the 
span of the study the cumulative amount of nucleic acid isolates summed 831 total 
nucleic acid samples, 561 RNA samples and 270 DNA samples. With this large amount 
of samples, there was a need for storage space and for clinical data management software 
that could curate the immense amount of clinical and genomic data that originated from 
the lung PCGA cohort. 
 
Current Clinical Metadata Management Practices 
Throughout clinical and healthcare related research, there have been continued 
challenges in collecting, utilizing, harmonizing, and managing the large amount of 
clinical data and metadata that is generated. In particular, two overarching challenges that 
have been highlighted are the inadequacies of databases to have easily accessible, 
analyzable data and inadequacies in connecting related healthcare data to other associated 
data types. In particular, this has become a growing issue with the increase in 
translational, molecular, and genomic research. Throughout the past decade there has 
been a considerable amount of work focused on the creation of systems that aid in 
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resolving these challenges. Industry, federal, and international agencies have become 
involved in the design, production, and marketing of solutions aimed at managing clinical 
data. The necessity of building software that aid in biorepository and curation of data is 
created from the aim to harmonize and connect related data in an accessible manner. (X. 
Wang et al., 2017) (Howe et al., 2008)  
One approach the National Academies of Science took in attempting to create 
accessible and connected sets of clinical data was to assemble members to participate on 
a multi-yearly basis to discuss the current state of database research and how to improve 
current best practice. The meeting is summarized in the Beckman Report, which reviews 
the discussions that occurred throughout the meeting. The most recent Beckman Report 
concluded that database researchers should focus on selecting the correct clinical data 
management software and recruiting trained individuals to compose a team to manage 
those systems. (Abadi et al., 2014)   
There are numerous industry distributors who have created storage and 
management programs that aid in the logging of clinical data and have become crucial in 
the healthcare research field. These software are of significant importance in large 
clinical research cohorts that analyze genomic sequencing such as type 2 diabetes 
research (Fuchsberger et al., 2016), hypertension studies (Surendran et al., 2016), 
cardiovascular research (Cabrera et al., 2019), and many others. The Beckman Report 
emphasizes the need for clinical sample and data management software for these cohorts 
as they create large amounts of data from genomic sequencing that is challenging to 
curate. In addition, thoughtful selection of knowledgeable members of the community to 
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prepare this data for entry, connect it with associated data, and continue management, is 
regarded as being equally important. (Abadi et al., 2014) The recommendations 
emphasized within the Beckman Report became important factors when approaching the 
revision and improvement of clinical metadata management within the lung PCGA 
cohort. 
 
Clinical Sample Metadata Management at BUMC 
Previously, sample metadata for the lung PCGA cohort was stored in a number of 
different formats. The FreezerPro program, produced by Ruro Inc. and currently owned 
by Brooks Scientific, was used to curate all data derived from the RNA, DNA, or 
biological samples in the lung PCGA cohort. The 2012 version of FreezerPro was used to 
manage sample tracking within the freezers at BUMC. Each sample entered into 
FreezerPro was assigned a single numerical value that corresponded to its logged sample 
information and physical location in the freezer.  
  By having a single program where data could be stored with the ability to be 
edited by different members of the lab corresponded to the needs of the lung PCGA 
cohort at that time. (FreezerPro Sample Management Software, 2007) FreezerPro had a 
report and audit function that allowed users to be able to track changes made in the 
system. This particular system is termed a “Blockchain Technology”. Blockchain 
technology is a type of program where individuals are given access to data within a 
particular network of information. When a single entity wishes to make a change to any 
of the data or request access to data within the set, there is a propagation of changes 
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across the network of information, alerting individuals to the change/request that had 
been made. The previous set of data that existed prior to the change/request is marked 
with a corresponding value and noted as to the user who performed the edit, who the 
requesting party was, and the date of and time of editing. (Blumzon & Panescu, 2019) 
 FreezerPro functioned as a blockchain style freezer management system that led 
to improvements in sample management upon its introduction into the lab. The program 
allowed for information curation into a singular source that could be accessed and edited 
by multiple members of our lab. The format of the program allowed for tracking of all 
changes made to the data and allowed for samples to be located in freezers with relative 
ease. With these improvements, however, there were multiple functionality issues that 
also existed. The capability to query the program for sample information required precise 
entry of data that was often cumbersome when data was entered incorrectly. Technical 
support of the program was also limited due to the older age and version of the program. 
The presence of these issues inevitably led to the decision to move away from the use of 
FreezerPro towards a newer freezer management program.  
 In conjunction with the recommendations from the Beckman report, our group is 
considering transitioning the data associated with the lung PCGA cohort to a newer 
clinical metadata management software program. I hypothesize that the introduction of an 
improved system will allow for increased accessibility and ease in sample data 
management and tracking, when compared to previous software. In further implementing 
the recommendations from within the Beckman report, our group will also be focusing on 
the recruitment of experienced members from within the lab to manage the upload and 
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updating of this data. Harmonizing patient and sample information that is not currently 
stored within any clinical metadata management software will be beneficial to uploading. 
The work performed in my thesis in the revision of clinical metadata management 
focuses on curating this particular data to allow for ease of access, uploading, and 
improved analysis within the future. 
 
DNA Isolation from Lung PCGA Organic Phase 
In conjunction, my thesis work aims to evaluate and identify a protocol to recover 
DNA from the RNA isolation organic phase samples. The fresh frozen endobronchial 
biopsies from the lung PCGA cohort used the RNeasy Mini® Kit for RNA isolation 
(RNeasy Mini Kit—QIAGEN Online Shop, 2020) DNA was not isolated from these 
samples concurrently using this kit during the initial RNA isolations; however, DNA may 
be able to be isolated from the remnant organic phase samples that was generated during 
these isolations. The lysis agent used in this kit is Qiazol™ created by Qiagen©.(QIAzol 
Lysis Reagent—QIAGEN Online Shop, 2020) This kit was used in isolation of all nucleic 
acid samples from the PCGA cohort.  
Although DNA is considered to be a stable macromolecule, it has been noted that 
being stored in -80°C freezers for a long period can lead to sheering of DNA upon 
thawing. (Baust, 2008) In addition, it has been noted that storing DNA at -80°C will keep 
the DNA in a stable condition once it has been processed and isolated from other 
contaminants. Storage at this temperature allows the DNA to be stable for upwards of 19 
freeze thaw cycles. However, when DNA has not been processed from other 
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contaminants, there is increased risk of degradation over extended periods of time when 
stored for longer than a 24-month period. (Wu et al., 2009).  The ability to isolate DNA 
from the lung PCGA organic phase samples will depend on the length of time the 
samples has been stored and the effect of the contaminants have on the DNA integrity. 
My aim for this process is to identify a protocol that can be used to isolate high-quality 
DNA from the banked organic phase samples within the lung PCGA cohort to benefit 



















 Sample organization, data curation, and accessibility are required in translational 
studies utilizing large clinical cohorts to advance scientific discovery. As part of our 
group’s efforts to generate a lung Pre-Cancer Genome Atlas, clinical samples and 
metadata were sent to BUMC from Roswell Park Comprehensive Cancer Institute. The 
systems available to organize and curate the samples and data upon receipt at BUMC had 
several shortcomings that resulted in a lack of organization and accessibility of the 
samples and data. The overall goals of my thesis were to curate the PCGA samples and 
clinical metadata to enhance sample and data accessibility that would ensure reproducible 
results in results in publications using this cohort. Additionally, I sought to identify a 
protocol to isolate high quality DNA from banked organic phase lung PCGA samples that 
had undergone RNA isolation. The samples in the lung PCGA cohort are precious and 
recovering DNA from these samples would enhance studies identifying somatic 
mutations associated with bronchial premalignant lesion development. This thesis 
describes the methods and results used to accomplish the following specific aims: 
1. Apply knowledge of current sample and clinical metadata practices to curate and 
enhance data management within the Lung Pre-Cancer Genome Atlas cohort.  
2. Identify a DNA isolation protocol to recover DNA from organic phase samples 
where RNA was isolated to enable DNA sequencing studies on the remaining 






Clinical Metadata Organization and Management: Patient Demographic Master 
Files    
Patient demographic information in the lung PCGA cohort was obtained from 
Roswell Park with disbursement of samples to BUMC and was updated over the course 
of the study. This resulted in several different files and file formats. My work was aimed 
at curating and harmonizing the data into a single master file. This file contains compiled 
information on: sex, race, baseline age, gender, ethnicity, smoking history at baseline of 
first screening visit, cancer history, lung cancer history, chronic obstructive pulmonary 
disease (COPD) presence and ranking. The original data files contained data dictionaries 
to help inform labeling, scoring, and titles in my master file.  
 
Clinical Metadata Organization and Management: Sample Master File 
      All information pertaining to the collected, isolated, and sequenced samples from the 
lung PCGA cohort was compiled into a sample master file. Each individual biological 
specimen collected in the lung PCGA cohort was isolated into RNA and DNA. For each 
of these isolated nucleic acid samples, there were multiple identifiers created during 
shipping and processing. The baseline sample ID, laboratory ID generated during nucleic 
acid isolation, and PCGA long ID were all compiled into this file. The curation of these 
identifiers came from multiple different files with varying format, contents, and versions. 
In creation of the master file, a single format was determined to allow for increased ease 
of use. All information that was considered identifiable was removed and entered in a 
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format previously outlined by the members of our group. Furthermore, all files were 
screened during the curation process to identify the most up-to-date information to 
guarantee all study data within the sample master file was current. 
      The corresponding histology of each sample and its preceding and progressive 
histology rankings per location was logged for all bronchial brushing and biopsy samples. 
R scripts were utilized to compute sample data pertaining to histologic lesion progression 
status. These histologic progression statuses were recorded and logged for each of the 
time points when a sample was collected for all patients. Any other known patient 
historical histology data that was not associated with samples collected in the study, but 
was recorded as clinical data, was noted in a separate section of the sample master file. 
Multiple sample master file versions were created for addition of other cohort pertinent 
information. BMI, future histologic updates, patient clinical follow up, and updated 
pathologic grading was integrated into updated file versions. The sample master file was 
structured to allow progressive additions of further cohort updates. A sample master file 
data dictionary was included within the patient demographic master file. The data 
dictionary also contained information from previously created documents referencing 
histology scoring values and bronchial location codes. 
 
Sample Storage Data Management and Updating 
 FreezerPro was a sample management and freezer tracking industry software that 
was purchased at BUMC and used for logging all information for the lung PCGA 
samples. Samples were logged into FreezerPro with user-defined fields for all data points. 
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These data points required constant update and upkeep to match any changes occurring 
with the sample. The consistency of data within the program varied due to inconsistency 
of data upload by the members of the laboratory. FreezerPro sample information was 
updated and matched to the information that had been compiled in the patient 
demographic and sample master file. 
 Physical sample reorganization occurred following the FreezerPro sample 
updates. The majority of the PCGA samples stored in a -80°C freezer were DNA and 
RNA samples. The infrequent updating of the location within FreezerPro following prior 
freezer reorganization events led to problems with finding specific samples. A handful of 
samples were found that were previously not known to exist within the freezers during 
the physical organization process. Finding these unknown samples created a need for an 
inventory to be created to allow for tracking of the remaining samples. An inventory was 
created for the remaining physical samples and logged with the sample master file. 
 
Organic phase DNA Isolation: Cell Culture 
  Cell cultures were used to test protocols that could be used to isolate DNA from 
organic phase samples. The strain of cells used was immortalized Airway Endothelial and 
Epithelial cells (AALEs). (Lundberg et al., 2002) Culturing of the AALEs followed the 
protocol for Human Bronchial Epithelial Cells distributed by Cell Applications, Inc. All 
cell culture work occurred in a Biological Safety Cabinet, which was sterilized with 70% 
alcohol solution prior to any culture work. Prior to any experiments, the blower and 




Organic phase DNA Isolation: Culturing AALE Cells 
 All culturing and sub-culturing of AALEs occurred within a Biological Safety 
Cabinet following the Human Bronchial Epithelial Cell Culturing protocol outlined by 
Cell Applications Inc. AALEs were supplied by senior members of the Mazzilli 
laboratory at Boston University and were cultured in Bronchial Epithelial Growth Media 
produced by Cell Applications Inc.. (Lundberg et al., 2002)  All cells were grown in a 
37°C incubator with 5% CO2. When confluence of the cell culture within the T-75 flask 
was noted as being greater than 60-80%, the AALEs were subcultured following 
protocols distributed by Cell Applications Inc. Following subculturing, cell pellets were 
isolated by microcentrifuge, all storage media was removed, and the pellet was stored in a 
-80°C freezer. 
 
Organic phase DNA Isolation: RNA Isolation and organic phase Generation 
 RNA isolation of AALE cells followed protocol distributed by Qiagen in the 
Qiagen miRNeasy Mini Kit. MaXtract gel tubes were used in association with this 
protocol for phase separation during RNA isolation. MaXtract tubes separated aqueous 
RNA containing phase and organic phase. Tubes containing organic phase from isolation 
reactions were stored at -80°C following aqueous phase removal during RNA isolation. 
RNA from cell culture samples was used as a control to confirm the existence of viable 
nucleic acids within the samples. All optical density measurements and concentration 




Organic phase DNA Isolation: “DNA Extraction from TRIZOL” Buffer creation 
 There are two solutions needed for the isolation of DNA from organic phase 
samples in the “DNA Extraction from TRIZOL” protocol. The first solution is a Back 
Extraction Buffer (BEB) that is used to remove the DNA from other contaminants within 
the organic phase solution. To make 250 uL of this solution, begin by adding  150 uL of 
millipore water into a beaker. Following this add in 118.2 g of Guanidine Thiocynate 
(Formula Weight 118.2 g), 3.68 g of Sodium Citrate (Formula Weight 294.1 g), and 
30.29 g of Tris free base (Formula Weight 121.14 g). Allow the solution to mix in the 
beaker using a stir bar and stir plate until homogeneous. Once this is done add in the 
remaining amount of millipore water (100 uL).  
 The second solution necessary for “DNA Extraction from TRIZOL” protocol is 
the 3M Sodium Acetate buffer, which is used during Comparative Genomic 
Hybridization (CGH) quality DNA isolation. To make 100 uL of solution, add in 24.61 
grams of sodium acetate to 80 uL of millipore water and allow the solution to mix until it 
is homogenous. At this point, add in the remaining 20 uL of millipore water. Once 
finished, titrate the pH using a pH meter and a strong acid/ base until within the desired 
5.2-7.0 pH range. 
 
Organic phase DNA Isolation: “DNA Extraction from TRIZOL” Baseline Protocol 
Remove the 2 mL microcentrifuge tube containing organic phase from the -80°C 
freezer that it was previously being stored in. Spin the microcentrifuge tube at 12,000 rcf 
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for 5 minutes at 4°C. Once complete, remove any remaining aqueous phase from the 
liquid-liquid interface. Take the 2 mL microcentrifuge tube, place into a Biological Fume 
Hood, and pipette 0.25-5 mL of BEB per 1 mL of TRIzol/QIAzol used for RNA 
isolation. Mix intensively by inversion for at least 3 minutes, or place on a shaker for 10 
minutes. Spin for 30 minutes at room temperature at 12,000 rcf. Transfer the upper 
aqueous phase and eventually save interphase for protein isolation. Add 0.4 mL of 
isopropanol per 1 mL of TRIzol/QIAzol used for original RNA isolation, mix by 
inversion, and allow 5 minutes for incubation at room temperature within the Biological 
Fume Hood. Take the sample after it has sat at room temperature, place into 
microcentrifuge and spin the sample for 15 minutes at 4°C at 12,000 rcf. Following this 
spin, remove the supernatant without disturbing the DNA pellet. Add 0.5 mL of 70% 
ethanol per 1 mL of TRIzol/QIAzol used for RNA isolation, and wash pellet by 
inversion. Spin the sample at 12,000 rcf for 15 minutes at 4°C in a microcentrifuge. Once 
complete, remove the ethanol and dissolve the pellet in about 400 uL of 1x TE buffer. 






Figure 1.  Graphical representation of the baseline protocol “DNA Extraction from 
TRIZOL”  
Protocol Outline. Graphical depiction of the steps of the baseline protocol of “DNA Extraction from 
TRIZOL” Beginning with the sample stored within the MaXtract gel tube, the figure depicts removal of the 
sample by syringe, then microcentrifuge spinning of the sample once BEB has been added. Following the 
down arrow depicts the removal of aqueous phase, addition of isopropanol and then another spin within the 
microcentrifuge. The supernatant is removed, 70% ethanol is added, and then the final microcentrifuge spin 
occurs. The 70% ethanol is removed and 400 uL 1X TE buffer is immediately added. The final arrow 
depicts continuation to of the protocol to CGH steps. 
 
Optional washing steps exist for CGH quality DNA by phenol, chloroform and 
isoamylacohol. Add 400 uL of phenol, chloroform, isoamylacohol (PCI) solution directly 
to the tube. Mix the phases intensively and place on a shaker for 10 minutes. Centrifuge 
at 12,000 rcf for 15 minutes at room temperature. The aqueous phase will be where the 
DNA will be found following this spin, transfer the aqueous phase to a new 1.5 mL 
microcentrifuge tube. Add another additional 400 uL of PCI solution and repeat the spin. 
Transfer any remaining aqueous phase to the new 1.5 mL microcentrifuge tube. Add 200 
uL of chloroform to the upper aqueous phase and centrifuge at 12,000 rcf for 15 minutes 
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at room temperature. Transfer the upper aqueous phase following the microcentrifuge 
spin into a new 1.5 mL tube, and add 20 uL of 3M Sodium Acetate pH 5.2-7.0. Mix and 
add 2 to 2.5 volumes of 100% ethanol, then mix by inversion. Spin this solution for 15 
minutes at 12,000 rcf at room temperature. Discard the remaining liquid and add 100 uL 
of ice cold 70% ethanol. Spin the tube for 15 minutes at 12,000 rcf at room temperature. 
Without disturbing the pellet, remove any supernatant left, and then resuspend the DNA 
pellet in 1x TE Buffer or DNAse free water. Allow the DNA to stay at room temperature 
for 5-6 hours or overnight. After this, measure the optical density of the DNA or run on 
agarose gel to check the DNA’s quality. DNA can be stored at 4°C until it is needed for 
use.  
 
Organic phase DNA Isolation: “DNA Extraction from TRIZOL” Streamlined 
Protocol 
 Following initial results of organic phase DNA isolation, portions of the original 
“DNA Extraction from TRIZOL” were edited for improved results. Organic phase 
samples were allowed to thaw on ice prior to processing. A 10cc syringe is used to 
remove the organic phase present underneath the MaXtract gel and place into a new 1.5 
mL microcentrifuge tube by passing through the lowest side of the gel. The speed for all 
centrifugation steps was reduced from 12,000 rcf to 8,000 rcf. 0.5 mL is the set amount of 
BEB that is added into samples during the protocol. 100% ethanol is used instead of 70% 
ethanol, and prior to TE buffer resuspension the pellet is set to dry for three to four hours 
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underneath a Kimwipe in the Biological Fume Hood. Only 100 uL of 1X TE buffer is 
added for resuspension. Samples are stored at 4°C indefinitely.  
  
 
Figure 2. Graphical representation of the streamlined protocol for “DNA Extraction 
from TRIZOL” 
Edited Protocol Outline. Graphical depiction of the steps of the streamlined protocol of “DNA Extraction 
from TRIZOL” Edits made from baseline alter the organic phase extraction by syringe, spin speed is 
changed from 12,000rcf to 8,000rcf, the amount of BEB used was set to 500 uL, the purity of ethanol was 
increased from 70% to 100%, and a drying time of 2-4 hours was implemented. 
 
Organic	Phase	DNA	Isolation:	Isolation	of	lung	PCGA	Sample 
 Isolation of DNA from the remnant samples within the lung PCGA cohort 
followed the streamlined protocol. The two samples selected for isolation were 
endobronchial biopsy samples 340 and sample 341. Both of the selected samples were 
previously endobronchial biopsy samples that were not isolated or stored within 





Clinical Metadata Organization and Management: Patient Demographic Master 
File 
 The creation of the Patient Demographic Master File compiled multiple 
documents into one final file that is in use by members of our laboratory and 
collaborators. The patient demographic master file has effectively curated a vast amount 
of information from numerous different locations to a single annotated file. Additional 
DNA-sequencing analyses correlating somatic mutations with clinical characteristics are 
currently using this new master file. Overall, the goal of reorganizing and condensing the 
data for all patients in the lung PCGA cohort was achieved allowing for the continued use 
of the data.  
 
Clinical Metadata Organization and Management: Sample Master File 
 Similar to the Patient Demographic Master File, the Sample Master File’s 
intended purpose was aimed at reducing the number of necessary documents within the 
lung PCGA cohort, while continuing to preserve data quality and allowing for continued 
thoughtful use of the data. After completion of the initial Sample Master File, additional 
versions have been created that incorporate additional cohort updates. The achieved ease 
of using this file, as well as updating it with additive data, has been accomplished 
successfully. For this reason, many members of our laboratory and other collaborators 
have begun using the table as a means to access all relative sample data contained in it.  
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 The Sample Master File has been used to check multiple other files that are still 
currently in use for the lung PCGA cohort. The file’s extensive data will likely become 
an indispensable resource for accessing any of the information related to the samples 
collected and processed in the lung PCGA cohort. As time moves forward, there will 
likely be further updated versions of the file when any further processing occurs or there 
is updated data that warrants addition to the master file. These file forms can be used to 
manipulate the data into a manner that is amenable to further data processing or for future 
scientific publication related analysis. In addition, the presence of a formatted and 
complete data dictionary for all codes and labels used within the patient demographic and 
sample master file has allowed for further ease in understanding the data contained in 
both tables. The completed data dictionaries resulted in better understanding and 
transparency as to what the values and coding annotations signify within all of the master 
files.  
	
Clinical	 Metadata	 Organization	 and	 Management:	 Sample Storage Data 
Management and Updating 
 Reorganization of the clinical metadata within the lung PCGA cohort was also 
accompanied by freezer and sample management updates. Beginning with the physical 
rearrangement of samples within the -80°C freezers that currently store the remnant 
samples from PCGA, the process led to significant space reduction for the study as well 
as additional sample discovery. The use of this sample inventory has led to initiation of 
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additional experiments using the remaining RNA and DNA samples from the lung PCGA 
cohort.  
 The physical management of the samples was also matched by updating of the 
freezer storage management software FreezerPro. The updating of the FreezerPro 
program  improved the capability to query and locate samples for additional experiments 
and processing. The updated system allowed samples in the freezer to be logged with all 
data from within the sample master file, enabling a multitude of different ways that a 
sample could be queried. Samples now had two to three different identifiers that 
corresponded to the particular sample, and for that reason, the sample now could be 
located using any of these identifiers. Additionally, any information that related to the 
sample that was not query-able, but was still relevant, was also included in the updating 
processes.  
 As of the beginning of 2020, the FreezerPro program became far more 
cumbersome to use following technical errors associated with loss of access into the 
program. For this reason our group has decided to move away from using this program 
for freezer sample management. In doing so, the program Lockbox has been chosen as 
the program that will be used in the future. Prior to this point all of the corresponding and 
updated data that was entered into the program was exported into a separate file. The file 
containing all information from the FreezerPro program will be formatted into a manner 
specified by the Lockbox program and then used to import all data. Following this import 
of data into Lockbox there will likely need to be further monitoring and update to the data 
within this program to ensure successful transitioning. It is likely that an individual will 
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need to manually enter any data that may not be correctly logged during transition, which 
I will be participating in. 
 
Organic Phase DNA Isolation: RNA Isolation  
 Results from RNA isolation were analyzed from all cell culture experiments to 
quantify optical density measurements and concentration. These values were used as a 
control to determine cell culture viability as an appropriate test system. The 
measurements for all RNA isolations performed throughout protocol testing showed that 
this experimental method yielded quantifiable amounts of high quality RNA, and 
similarly quantifiable amounts of high quality DNA. These values are reported in Table 
1.0. The	 optical	 density	 absorbance	 spectra	 of	 all	 samples	were	 analyzed	 using	 a	
Nanodrop	 2000	 and	 evaluated	 in	 comparison	 to	 material	 published	 by	 Thermo	
Fisher	 Scientific	 Inc.	 (T042-TECHNICAL	 BULLETIN	 NanoDrop	 Spectrophotometers,	
2009) 
Table 1.0 RNA optical density measurements for cell culture RNA samples  
Sample ID Concentration  A260 (Abs.) A280 (Abs.) A260/280 A260/230 
12_13 Cell Culture 1 699.8 ng/uL 17.49 8.664 2.02 1.64 
12_13 Cell Culture 2 693.7 ng/uL 17.34 8.572 2.02 1.2 
02_11_20 RNA A 466.7 ng/uL 11.66 5.804 2.01 1.34 
02_20_20 RNA A 424.7 ng/uL 10.61 5.276 2.01 1.27 
02_20_20 RNA B 490.7 ng/uL 12.26 6.091 2.01 0.96 
02_20_20 RNA C 215.3 ng/uL 5.383 2.682 2.01 0.65 
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02_20_20 RNA D 427.0 ng/uL 10.67 5.328 2.0 1.08 
 
The RNA optical density values in Table 1.0 show evidence of sufficient amount 
of nucleic acid within the cells of the AALE cell culture to allow for testing of organic 
phase DNA isolation protocols. The sample information shows that the RNA isolated 
from the AALE cell cultures is present in large concentration, The quality of the RNA, 
evidenced by the A260/280 ratios being roughly 2.0 for all samples, indicates high 
sample purity for RNA samples. (T042‐TECHNICAL BULLETIN NanoDrop 
Spectrophotometers, 2009) With these factors, this system is a good model for testing of 
organic phase DNA isolation due to the large amount of high purity nucleic acids present 
within the sample. 
 
Organic Phase DNA Isolation: “DNA Extraction from TRIZOL” Baseline Protocol 
 Multiple protocols were tested for the isolation of DNA from organic phase 
samples. Of the many different protocols tested, the “DNA Extraction from TRIZOL” 
protocol was chosen as it had the least contamination and highest quantifiable yield 
following baseline experimentation. The results for this selected protocol were shown to 
have significant high quality DNA present after multiple attempts of the protocol on 
AALE cell cultures, and thus this protocol was chosen over other tested protocols.  
The initial results from the baseline protocol “DNA Extraction from TRIZOL” 
had a handful of issues. In the outset, the protocol yielded significant issues with creating 
hyper-dense DNA pellets that would not resuspend within the 1x TE buffer solution. 
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Multiple attempts to vortex, repeated pipet aspiration, inversion, and addition of excess 
BEB had no effect on the density of the pellet (Figure 3B). Pellet density was a consistent 
problem that led to a lowered DNA yield for the respective sample that was being 
isolated. The lowered yield was also accompanied by reduced optical density 
measurements and high amounts of contamination (Figure 3A). Additionally, there were 
issues with the MaXtract gel used during the RNA isolation steps, which led to further 
contamination and visible spread of debris surrounding the DNA pellet after DNA 
isolation (Figure 5B). The MaXtract gel is impenetrable by all liquid solutions used in the 
“DNA Extraction from TRIZOL” protocol, requiring extraction of the organic phase prior 
to any attempts to isolate DNA. Furthermore, there were noticeable amounts of 
absorbance spectra abnormalities that supported the presence of certain contaminants 
within the DNA pellet or still present from the isolation processes (Figure 4A). These 
issues were further resolved in the streamlining and editing process that occurred with 
this protocol prior to attempting any isolations on the respective samples remaining from 




Figure 3. Optical density quantification from organic phase DNA isolation 
01/03/2020 
(A) Optical density quantification via spectrophotometry used for evaluation of organic phase DNA 
isolation sample purity and concentration on 01/03/2020. The elevated 260 value indicates likely 
contamination from excess guanidine isothiocynate present within the BEB. All associated value 
measurements are listed in Table 2.0. (B) Pellet image from post-DNA isolation observed in a hyper-dense 





Figure 4. Optical density quantification from organic phase DNA isolation 
01/30/2020  
(A) Optical density quantification via spectrophotometry used for evaluation of organic phase DNA 
isolation sample purity and concentration on 01/30/2020. Elevated 260 and 230 values are indicative of 
contamination from guanidine isothiocynate from excess BEB and QIAzol/proteinaceous contaminants, 
respectively. All associated value measurements are listed in Table 2.0 (B) Pellet post-DNA isolation 
observed in a ribbon-form at the base of the tube. The ribbon-form pellet was associated with high amounts 
of contamination from Qiazol. 
  
 
Figure 5. Optical density quantification from organic phase DNA isolation 
02/18/2020  
(A) Optical density quantification via spectrophotometry used for evaluation of organic phase DNA 
isolation sample purity and concentration performed on 02/18/20. The elevated 230 value present is 
indicative of contamination from proteinaceous compounds and MaXtract gel remnant. All associated value 
measurements are listed in Table 2.0 (B) Pellet post-DNA isolation observed with proteinaceous or 
MaXtract gel remnant material above the DNA pellet. The elevated 230 value was associated with this 
contamination. 
Table 2.0 Organic phase baseline protocol DNA optical density measurements  
Sample ID Concentration  A260 (Abs.) A280 (Abs.) A260/280 A260/230 
OP 12_13 DNA 1 192.6 ng/uL 
 
3.853 2.04 1.89 47.78 
OP 12_13 DNA 2 246.0 ng/uL 4.921 2.784 1.77 8.03 
OP 01_30 DNA B 348.2 ng/uL 6.964 4.193 1.66 0.55 
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OP 12_20 DNA 1 79.2 ng/uL 1.583 1.31 1.21 0.5 
OP 12_20 DNA 2 44.1 ng/uL 0.882 0.836 1.06 0.78 
OP 11_15 DNA B 45.2 ng/uL 0.904 0.85 1.06 0.78 
OP 02_18 DNA A 47.2 ng/uL 0.944 0.675 1.40 2.16 
 
The first two samples contained in Table 2.0, exhibit a large A260/230 ratio 
corresponding to contamination from Guanidine Thiocynate likely from the BEB. Further 
visible in these results are issues with contamination from Qiazol or other phenolic 
compounds as present by the reduced A260/280 ratios in Samples OP 12_20 DNA 2 and 
OP 11_15 DNA B. Additionally, the decreased concentration in sample concentration 
within OP 02_18 DNA A is likely from lack of purification with 70% ethanol or from 
over-dilution with 400 uL 1x TE Buffer. 
 
Organic Phase DNA Isolation: “DNA Extraction from TRIZOL” Streamlined 
Protocol  
 As mentioned previously, the organic phase DNA extraction via the “DNA 
Extraction from TRIZOL” baseline protocol was edited to improve the respective DNA 
isolation outcome. The streamlined protocol aimed to alleviate some of the particular 
absorbance and contamination issues that had been experienced in the baseline protocol. 
The first edit that was made related to the alteration of microcentrifuge spin speed from 
12,000 rcf to a reduced speed of 8,000 rcf. The reduction in speed aided in decreasing the 
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hyper-dense pellet from forming during processing attempts, and aided in the re-
suspension in 1x TE buffer. Issues relating to contamination and the MaXtract gel being 
impenetrable to solution during processing were solved using a 10 cc syringe to pass 
through the gel at the lowest point, carefully draw up only the organic phase avoiding 
interphase remnants, and transfer into a new 1.5 mL tube. Additionally, using 70% 
ethanol was changed to using 100% ethanol, which increased concentration and DNA 
aggregation into a pellet. The problem of obscure Guanidine Isothiocynate contamination 
was solved by reduction of BEB from 700 uL to 500 uL in the initial steps of the 
protocol. A reduced amount of 1x TE buffer was used yielding a heightened 
concentration upon measurement. A drying time of 2-4 hours was implemented prior to 
addition of 1X TE buffer to allow for evaporation of ethanol from the pellet. The drying 
time was performed with a Kimwipe covering the top of the microcentrifuge tube while 
placed in a hood. 
 In performing the streamlined protocol, the DNA pellet upon isolation was not 
hyper-dense alike to prior pellets (Figure 6B). All optical density measurements exhibited 
pure values for DNA samples (Figure 6A). The A260/280 and A260/230 ratios, 1.42 and 
1.43 respectively, indicate that there were reduced amounts of contamination and 
heightened sample purity compared to prior isolations. Sample concentration was 97.9 




Figure 6. Optical density quantification from organic phase DNA isolation 
02/21/2020  
(A) Optical density quantification via spectrophotometry used for evaluation of organic phase DNA 
isolation sample purity and concentration performed on 02/21/20. The 260 and 230 values correspond to 
normalized DNA optical density values when there is a large amount of nucleic acid present. (B) Pellet 
post-DNA isolation was observed as being far less dense than previous pellets and later resuspended into 
1X TE buffer.  
Additionally, following storage of these samples within the freezers present 
within the Mazzilli laboratory, there was a noticeable increase in the concentration 
(ng/uL) of the DNA sample. The overall absorbance spectra did not change drastically to 
a more or less suitable direction, the increase in samples concentrations noticeably 
increased by amounts of 5-15 ng/uL. The visible pellet within these solutions was not 
noted to have changed in size in the multiple samples that were reanalyzed. 
 
Organic Phase DNA Isolation: Isolation of Lung PCGA Samples 
	
 37	
In the selection of which of the remaining samples to use for the analysis of the 
DNA isolation from organic phase protocol, multiple factors were analyzed pertaining to 
the RNA isolated and sequenced corresponding to these samples. The sample type, 
bronchial brushing vs. endobronchial biopsy, the associated RNA Median Transcript 
Integrity Number (TIN) value, and the associated concentration (ng/uL) of RNA isolated 
originally, were all evaluated prior to selection. For sample type selection, bronchial 
brushes are known to have a lower quantity of RNA and DNA due to a lower cell count 
collected from a bronchial brushing comparative to a whole tissue biopsy. The Median 
TIN for these values has a positive correlation to the values associated with both mRNA 
fragment size and the overall quality of the RNA as dictated by the RNA sample’s RNA 
Integrity Number (RIN).  (L. Wang et al., 2016) The RIN can also be used as an indicator 
for the quality of the sample when it was previously used for RNA isolation. With this, 
the RNA quality is correlated with the general quality of the sample, so the higher the 
TIN and RIN values for these samples, the assumption stands that their would be higher 
likelihood that they would also have corresponding high quality DNA. (L. Wang et al., 
2016) Alike to this ideology, if a sample had a larger concentration of RNA upon initial 
isolation, it is likely that there would be a higher amount of DNA present as well. Using 
these three different indicators, the samples that remained from the lung PCGA cohort in 
the organic phase were screened and triaged into groups with the best likelihood for 




 When processing the two endobronchial biopsy samples, it was noted that there 
was aqueous phase still present in both of the samples, so prior to isolation of DNA the 
samples underwent an aqueous phase removal step. With this, the proteinaceous 
interphase that was present likely remained within the organic phase solution and could 
have become grounds for contamination. In addition, there were visible black flecks 
within the pellet of both samples that could also be from interphase or other contaminants 
related to the age of the sample.  
 The endobronchial biopsy samples that were used for isolation were lung PCGA 
samples 340 and 341. These two samples were chosen for having a noticeably larger 
Median TIN value and higher concentrations of RNA compared to their counterpart 
samples. Analyzing the samples following isolation revealed the information shown in 
Table 3.0. 
Table 3.0 Lung PCGA organic phase DNA optical density values 
Sample ID Concentration A260 A280 A260/280 A260/230 
PCGA 340 DNA 84.7 ng/uL 1.695 1.21 1.4 0.91 
PCGA 341 DNA 263.6 ng/uL 5.272 3.355 1.57 0.93 
 
In evaluation of the optical density absorbance spectra, the two isolated DNA 
samples revealed heightened A230 & A270 values as shown in the figures 7.0 and 8.0. In 
particular, the heightened A270 value is more prevalent in PCGA sample 341 
comparative to sample 340. These heightened measurements could be a sign of 
perspective contamination from Qiazol/Trizol during the RNA isolation process or from 
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other phenolic and proteinaceous compounds present during the organic phase DNA 
isolation process. The contamination could originate from proteinaceous contaminants 





























 Collection, harmonization, and thoughtful management of clinical metadata and 
sample processing are particularly challenging when managing healthcare related and 
clinical research cohorts. Current studies are accompanied by protocols containing multi-
omic translational processes, in which thoughtful integration of the large amount of 
generated data is integral to ensuring the continuation of cutting edge discoveries and 
scientific conclusions. (X. Wang et al., 2017) My work with the lung PCGA cohort began 
in determining a structured and thoughtful manner to harmonize the data the study had 
generated into one cohesive and accessible form. Analyzing sources entailing best 
practices for metadata management and current approaches to managing big data in 
healthcare research, I implemented recommendations set out by the Beckman Report. 
(Abadi et al., 2014) Introduction of a comprehensive sample and data management 
system came from discussions with members of our group, beginning with harmonization 
of the numerous files into consolidated single master files and a decision to shift away 
from the previously FreezerPro software. Both of these approaches highlight the success 
of implementing the emphasized measures outlined in the Beckman Report. 
Analysis of the overall data management improvements that have come from my 
work has shown increased organization of all curated clinical metadata and sample 
information. In evaluation of the numerous alterations that have occurred in the dataset, 
there has been an overall revision to the organizational structure of the data in the cohort. 
By reducing the number of needed files for the patient demographic information to one 
singular file containing all pertinent information, the time spent searching for specific 
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information is reduced. Patient demographic information became drastically easier to 
access and the information relating to all samples collected throughout the entire timeline 
of the cohort has additionally been placed into one structured file. The sample master file 
has allowed for enhanced organization of all sample information. Following completion 
of this table, there has been use for progression of DNA-sequencing analyses occurring 
with collaborators of our laboratory. The increased use by the members of our lab 
matches what was originally hypothesized when beginning my work and has ensured the 
continuation of scientific discovery. (X. Wang et al., 2017)(Howe et al., 2008) The work 
that has been done with file organization and clinical metadata compilation will continue 
to provide ease when using the study data progressing forward. 
 The updated data stored in the FreezerPro program increases the continuity and 
accessibility of the lung PCGA data. By improving this continuity, it allows for samples 
to be queried easier, but also creates a more complete management system overall. 
Though FreezerPro will no longer be in use by our lab in the future, the complete set of 
data will be uploaded into the Lockbox system. There are going to be further updates to 
the data set, the software and master files that have been updated will allow for continued 
simplified integration of data. Once all of the files have been uploaded into the Lockbox 
system, work will need to be done to ensure ease in data usage and to ensure that all of 
the data transitioned correctly. 
 The selection process of organic phase DNA isolation required testing of multiple 
protocols prior to determining which one had more successful results comparative to 
other tested protocols. After multiple alterations to this protocol, the final result of testing 
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yielded DNA that had concentration and optical density measurements that would be 
viable for DNA use in sequencing. All alterations that were made on the protocol were 
made in comparison to other organic phase and traditional DNA isolation protocols. (Tan 
& Yiap, 2009) In discussion of the results, it is noted that the model system of cell culture 
organic phase DNA isolation was expected to have better results than any attempted 
PCGA organic phase samples due to the age of the samples. Samples stored for greater 
than 24 months have shown high amounts of DNA degradation when isolated. (Wu et al., 
2009)  
Notably, it is interesting to see that the isolated organic phase DNA samples have 
increased concentration over time when stored within a 4°C freezer for two to three 
weeks. After evaluating the optical density and concentration of all isolated samples, 
follow up measurements to evaluate possible dissolution of the pellet over time were 
performed. When evaluating the concentration of these samples, the majority had 
increased in concentration by 5-15 ng/uL. The increase is likely due to minute dissolution 
of the pellet during the time that it was being stored in the 4°C freezer. There was no 
noticeable change to the appearance of the pellet visibly and there were only minute 
changes to the optical density measurements of the isolated DNA. The increase in 
concentration is interesting to note as it may indicate further possibility of pellet 
dissolution into the storage media following original isolation. It is not known as to 
whether the increased concentration may aid in the capability for a sample to be viable 
for genomic sequencing as contamination was still present in these samples.  Further 
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measurements and monitoring of concentration increase outside of the two to three week 
period will have to be performed. 
During processing of the two lung PCGA organic phase samples, the DNA pellet 
that was isolated did not remain attached to the tube wall during removal of the BEB 
supernatant. This issue did not occur in the testing phase of the protocol. There is 
likelihood that this occurred because of contamination from degraded proteinaceous 
material or that the centrifugation speed was not fast enough throughout the DNA 
isolation protocol. Some of the DNA pellet from sample 340 was lost when trying to 
remove the supernatant BEB solution during processing, which could contribute to the 
slightly lowered final DNA concentration. DNA samples were stored in 100 uL of 1X TE 
buffer for final resuspension, so the final concentration of these samples could be 
concentrated further if necessary.  
 In evaluation of the optical density measurements and concentration for the lung 
PCGA cohort samples, it was noted that there was a significant amount of contamination 
associated with the DNA from these two samples indicated by the lowered A260/280 
ratio. It also should be noted, that the black spots present within the corresponding DNA 
pellet further the idea of contamination by Qiazol solution or other proteinaceous 
compounds that would cause alterations in the associated optical density measurements. 
It is probable that the presence of proteins within the interphase of the isolation could 
have led to increased contamination, as both of these samples were not isolated or stored 
in a MaXtract gel tube.  
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Comparing the associated absorbance spectra for Sample 340, 341, and Thermo 
Scientific published absorbance spectra, it is apparent that each of the isolated DNA 
samples suffered from contamination.  (T042‐TECHNICAL BULLETIN NanoDrop 
Spectrophotometers, 2009) Both of the samples suffered from an increased absorbance at 
230 nm, which is generally associated with contamination of phenolic compounds such 
as Qiazol, or from excess proteinaceous compounds. The contamination from Qiazol is 
expected for these samples due to the sample age bring greater than the 24 month period 
associated with DNA shearing upon thawing. (Wu et al., 2009)  The contamination of 
Qiazol is visible in the absorbance spectra of both samples, but more prominent in sample 
341, as the absorbance at 230 nm is much higher comparative to sample 340. Sample 341 
also has a higher absorbance at 270 nm comparative as well, which could be linked to 
further Qiazol contamination. Though it is not as likely, the increased values at 270 nm 
could also be from remnant BEB sample leading to Guanidine Thiocynate contamination 
still present following isolation. Due to the signs of contamination and reduced A260/230 
value, the chance that these samples could be used for sequencing is unlikely.  In 
comparison of these results to DNA isolated from frozen tissue, the concentration of 
DNA is similar across both groups. When evaluating the optical density ratios, the 
A260/280 and A260/230 ratios are lower in the organic phase isolated DNA samples.  
The streamlining of the “DNA Extraction from TRIZOL” protocol has identified 
a successful protocol for the isolation of DNA from organic phase. Though I was unable 
to isolate high quality DNA from all organic phase samples from the lung PCGA cohort, 
the overall implication that the protocol is successful and can be used to isolate DNA 
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from these samples is significant. By identifying and editing this protocol, I believe that 
there will be a positive impact moving forward for further isolations on the remaining 
samples. Currently there are 69 samples still stored as organic phase at Boston 
University. Future directions for this work are aimed at the complete isolation of all the 
remaining organic phase samples to isolate high quality DNA that can be used for 
sequencing.  
I believe that the protocol that is currently being used to isolate DNA from 
organic phase samples should be edited further. The issues that occurred with 
contamination in sample 340 and 341 may prevent the isolated DNA samples from 
undergoing DNA-sequencing. Refining the protocol further could allow for future 
isolated samples to be viable for DNA-sequencing purposes. The focus of these edits 
would prioritize the elimination of contaminants that were present within DNA from 
sample 340 and 341. In particular, removal of proteinaceous interphase contamination 
should be prioritized. I believe this can be achieved by an additional spin at 12,000rcf of 
the organic phase sample prior to addition of BEB and following removal of remnant 
aqueous phase and interphase. This additional spin will further separate out aqueous 
phase and interphase components from the organic phase that can be removed prior to 
addition of BEB. Though this will not be an issue in MaXtract tubes, all samples not 
stored in MaXtract tubes should have an outcome of reduced proteinaceous 
contamination. Isolation of DNA from samples stored in MaXtract gel tubes may have 
less contamination from proteinaceous compounds due to the presence of the gel.  
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 Overall, the work that I have completed within my thesis has yielded an 
improvement to multiple aspects of the lung PCGA cohort. Curation of the metadata into 
a single formatted file with data dictionaries has allowed for improved ease and 
accessibility to patient and sample information, which will allow for continued scientific 
progression and discovery. The updates to the FreezerPro program have led to 
simplification of the sample tracking process within the cohort and consolidated all 
information on lung PCGA samples to allow for future upload into an improved tracking 
software. The streamlining of a protocol to isolate DNA from organic phase samples has 
given new purpose to a previously unused sample. Once the protocol has been refined 
with further updates, these isolations have the potential to increase the amount of viable 
DNA samples. Through completing my thesis work, I have gained a new understanding 
of an area of clinical research management that I previously had no knowledge of while 
simultaneously revising metadata curation, priming future expansion projects, and 
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